Australia's largest stock trading and investment forum Australia's #1 stock forum

SRX

Click for more information

0.00%

17.5¢ sierra rutile holdings limited

Destined to fail, page-40

First 40 Last

Share
Profile

Follow
slashj

330 Posts.

26/03/15

13:17

Post #: 14985100
Share

Originally posted by 6186mark ↑

Cafa, I don't know whether to thank you or curse you for making me research into this further and relive the horrors of uni-level maths. But in my research I have found out a couple of references of interest.

I like this one: http://www.ncbi.nlm.nih.gov/pubmed/25487708?dopt=Abstract. And the key sentence within this abstract is this: Assuming an increase in the median PFS from 9.4 months to 12.5 months with the addition of SIRT to mFOLFOX6, recruiting >=450 patients will be sufficient for 80% power and 95% confidence.

So the key question for overall PFS is whether the MEDIAN PFS increases by 3.1 months. Not the mean. Before I read this abstract I did not realise this.

So in a study of 600 patients, of which half are control, what is the PFS increase of the 151st patient in the list of trial patients, in ascending order of PFS improvement (i.e. actual PFS - expected PFS)? If we assume that 120 patients do not improve PFS at all (or minimally), we are looking at the 31st patient in the list of 180 liver-only patients, sorted in order of increased PFS.

So unless I have mis-interpreted this, we now know for a fact that the 31st patient in the list did not experience PFS improval of 3.1 months. Otherwise the primary outcome would be a success.

But because the liver only group Secondary Outcome WAS a success, we now also know that the median of this subgroup - i.e. the 91st liver-only patient - did experience PFS improval of 3.1 months.

So in summary (assuming minimal improvement on the patients who had tumours outside the liver), of the liver-cancer only patients, We have 30 who definitely had PFS improvement of less than 3.1 months, and 90 who definitely had PFS improvement of greater than 3.1 months. The other 60 we have to wait on until we see the detail.

To me this is like a light bulb going off and it explains - perhaps - why this trial was not destined to fail. Because if ALL the liver-only patients showed more than 3.1 months PFS improvement, the overall PFS for the group would still be >3.1 if measured by the improvement in the MEDIAN patient.

And of course all the above analysis may be wrong, as I am learning as I go along

Expand

Survival rates are nearly always expressed as Medians, it's a "stats thing" as Means can be ill defined, because what is the X-axis? number of people or time (days, months)? The distribution of the X-axis then may not be normal. Median has other benefits, it can be quicker to gauge the trial outcome as not all patients need to be tested, and it is more intuitive to explain to patients.

I am not sure why it was inferred that the trial was destined to fail? Trials maybe conceived with a degree of emotion ("want to succeed!") but are modelled and tested objectively (statistical modelling, power analysis) before patient testing.

"if ALL the liver-only patients showed more than 3.1 months PFS improvement, the overall PFS for the group would still be >3.1"
Probably missing your point here, but that will be correct for mean or median, because in this instance you have defined 100% of your group, it is statistically impossible for the group to have <3.1.

SRX Price at posting: $20.27 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 31 more messages in this thread...

First 40 Last

Add SRX (ASX) to my watchlist